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Introduction
Uterine fibroids (leiomyomas or myomas) are the most com-
mon pelvic tumors and the most common benign tumors in 
women [1,2]. It is estimated that 60% of reproductive-aged 
women are affected, and 80% of women develop the disease 
during their lifetime [3-6].
Uterine fibroids are monoclonal tumors that arise from the 
uterine smooth-muscle tissue [7,8]. The reasons fibroids de-
velop and grow are not well understood, but many factors 
are recognized as growth promoters, with sex steroids, estro-
gen and progesterone, being the most frequently studied [9-
11]. Increasing age up to menopause, with incidence peaking 
in the fourth decade, Black ethnicity, and obesity are the well-
known risk factors for fibroids [12-14]. Both reproductive 
and environmental factors have been described. Some of the 
most common reproductive factors include nulliparity, early 
menarche, and the use of oral contraceptives before 16 years 
of age. Additional environmental factors, such as diet, par-
ticularly vitamin D deficiency, and environmental toxins, are 
the subject of ongoing investigations [15,16]. Some dietary 
factors, including increased consumption of fruits, vegetables, 
and low-fat dairy products, are associated with a reduced risk.
The majority of women with uterine fibroids either remain 
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asymptomatic or develop symptoms gradually over time. 
When patients are symptomatic, the number, size, and/
or location of fibroids are critical determinants of its clinical 
manifestations. Commonly reported symptoms include heavy 
menstrual bleeding, dysmenorrhea, noncyclic pain, urinary 
symptoms, fatigue, and constipation [5,17]. The association 
between infertility and fibroids is limited. A recent meta-
analysis demonstrated that submucosal, intramural, and sub-
serosal fibroids have different effects on fertility, and they are 
mostly related to submucosal lesions resulting in implantation 
defects [18-20].
Hysterectomy was considered the only curative solution for 
fibroids; however, alternate medical treatments that preserve 
fertility and avoid invasive surgery, with high efficacy, and a 
desirable side effect profile are now available. We reviewed 
the use of well-known medical treatments, both as adjuvant 
therapy and as primary therapy. The discussion focuses on 
gonadotrophin-releasing hormone (GnRH) analogues, the 
levonorgestrel-releasing intrauterine system (LNG-IUS), selec-
tive progesterone receptor modulators (SPRMs), and aromatase 
inhibitors (AIs). Each carries its own safety and effectiveness 
profile, and the treatment of fibroids must be individualized de-
pending on such factors as the patient’s age, signs and symp-
toms, sustained reduction of fibroid size, and maintenance or 
improvement of fertility, while minimizing side effects.
Combination oral contraceptives
Observational data support the use of oral contraceptives to 
reduce menstrual bleeding in women with fibroids [21]. As 
uterine fibroid growth is stimulated by both estrogens and 
progestins, Combination oral contraceptives (COCs) were con-
sidered a risk factor for fibroid growth, in the past. However, 
a recent meta-analysis suggests that uterine fibroids should 
not be considered a contraindication for COC use [22]. In the 
short-term, COCs can be used to improve heavy menstrual 
bleeding associated with fibroids, primarily through their 
suppressive effects on endometrial proliferation, but overall 
they have no effect on decreasing uterine fibroid volume or 
uterine size [21,22]. Some studies suggest that COCs are not 
recommended for myoma-related symptoms [23], whereas 
some use COCs, but close monitoring of uterine myoma and 
uterine size is recommended [24]. A randomized controlled 
trial comparing COCs with a LNG-IUS for the treatment of 
fibroids showed the superiority of the LNG-IUS, but the COC 
still demonstrated a reduction in menstrual blood loss and no 
significant change in the volume of the tumors [25]. Although 
there is a lack of robust evidence regarding the efficacy of 
these medications, trials with COCs may still be effective in 
some women with uterine fibroids due to their advantages of 
easy accessibility, oral administration, and low cost [26].
Progestins
The cyclic use of progestins for bleeding control has been 
used in cases of non-organic abnormal uterine bleeding, such 
as perimenopausal bleeding and endometrial hyperplasia-re-
lated bleeding. Although often administered in the treatment 
of uterine fibroids, as with previous COCs, there is some opin-
ion that progestin does not recommend treating symptoms 
associated with uterine fibroids [23]. There is a lack of high-
quality evidence assessing the efficacy of these medications, 
and they may even promote uterine fibroid cell growth. In one 
study, depot medroxyprogesterone acetate (DMPA) was used 
in 20 women with uterine fibroid-induced bleedings [27]. Af-
ter 6 months, 30% were amenorrheic, 70% had an improved 
bleeding pattern, and 15% had an increase in hematocrit. 
Uterine and fibroid volumes were decreased by 48% and 
33%, respectively. Two other studies assessing the efficacy of 
oral progestogens in women with fibroids were conducted. 
One of them compared lynestrenol, an oral progestogen, with 
leuprolide, a GnRH agonist, and demonstrated no significant 
difference between the treatments in improving pelvic pain 
and uterine bleeding. The other study, which included only 
18 patients, compared dienogest, an oral progestogen, with 
leuprolide, demonstrating a significant decrease in tumor vol-
ume with both treatments (50% and 60%, respectively) [28]. 
Treating uterine fibroids with progestogens may be effective 
in some cases, but such treatment has been associated with 
histopathological changes that may be mistaken for leiomyo-
sarcoma or smooth-muscle tumors of unknown malignant 
potential, such as an increase in cellularity and mitotic activity.
LNG-IUS
In 2009, the Food and Drug Administration (FDA) approved 
the LNG-IUS to treat heavy menstrual bleeding in women 
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who opt for an intrauterine device for contraception. As it 
was well-known as an effective treatment for non-organic 
abnormal uterine bleeding, its use for treating uterine fibroid-
related bleeding, was soon investigated. A randomized 
controlled trial comparing LNG-IUS with a low-dose COC 
in women with fibroids, demonstrated that the former was 
more effective in reducing uterine fibroid-related bleeding 
than the latter, although the trial suffered from high attrition 
rates and assessed uterine bleeding in only 22 patients [25,29]. 
In the LNG-IUS group, there was a significant decrease in 
menstrual blood loss and uterine volume, while hematocrit 
increased. In a systematic review by Zapata and colleagues 
[30], they reported that menstrual blood loss decreased in the 
11 studies included in their analysis. These investigations also 
demonstrated an increase in hemoglobin, hematocrit, and 
ferritin. Although numerous studies indicate improvement 
in menstrual bleeding and hemoglobin levels when used in 
women with uterine fibroids, they do not demonstrate an 
appreciable change in fibroid volume, as measured by mag-
netic resonance imaging (MRI) and other imaging modalities 
[29,31,32].
Once inserted, the LNG-IUS is effective for up to 5 years, 
thus potentially providing women with a long-term treatment 
option. Because it is not administered systemically, minimal 
side effects are reported and no additional patient’s compli-
ance after insertion is required, as there is no need for daily/
monthly injections. However, given the increased risk of expul-
sion, it is probably an effective option in selected symptomatic 
women with no endometrial distortion.
GnRH agonists
Native GnRH, a decapeptide, is produced and released in a 
pulsatile pattern from the hypothalamus. GnRH agonists are 
synthetic peptides structurally close to the natural GnRH mol-
ecule, but they are  more potent and have a longer half-life 
than native GnRH [33,34]. When administered, they increase 
follicle-stimulating hormone (FSH) and luteinizing hormone 
(LH) secretion initially, known as the flare effect. After that, 
they subsequently cause receptor down-regulation, followed 
1–3 weeks later by a hypogonadotropic hypogonadal state, 
often termed — “pseudomenopause”. This hypoestrogenic 
state contributes to the pharmacologic efficacy of GnRH ago-
nists, as leiomyoma growth is stimulated by estrogen. Several 
studies have shown that tumor shrinkage is proportional to 
the number of estrogen receptor (ER)-positive cells [33,35].
GnRH agonists have been most extensively studied for the 
treatment of symptomatic uterine fibroids, especially adjuvant 
preoperative medical therapy. The Cochrane Systematic Re-
view, a systematic review of 26 randomized controlled trials to 
determine the efficacy of GnRH agonists when before hyster-
ectomy or myomectomy, showed notable therapeutic benefits 
[36,37]. A significant improvement in both pre- and postop-
erative hemoglobin levels and significant reductions in uterine 
volume, uterine gestational size, fibroid volume, and duration 
of hospital stay were noted. In addition, blood loss and rate 
of vertical incisions were also reduced for both myomectomy 
and hysterectomy [28]. The usage of GnRH agonists seems 
to be more beneficial in cases of large uterine fibroids (>10 
cm) if the myomectomy is to be performed laparoscopically, 
thus reducing operative time, intraoperative bleeding, and the 
risk of blood transfusion. Besides, GnRH agonists may also 
be beneficial prior to hysteroscopic resection of submucosal 
myomas, and one randomized controlled trial demonstrated 
that the preoperative use of GnRH agonists helped decrease 
operative times, fluid absorption, and the difficulty of the hys-
teroscopic procedure.
Despite FDA approval, menopausal symptoms, such as hot 
flashes and atrophic vaginitis, and a decrease in bone mineral 
density (BMD) after long-term use limit GnRH agonists to 
short-term adjuvant therapy in most patients. As a result of 
these hypoestrogenic side effects, long-term GnRH agonist 
therapy necessitates the use of hormonal add-back therapy 
to offset some of the hypoestrogenic symptoms and preserve 
BMD [38,39]. Furthermore, GnRH agonists treatment is as-
sociated with histological changes in uterine fibroids that may 
complicate surgical intervention. Treatment with leuprolide 
acetate preoperatively can cause myoma degeneration and 
obliteration of the interface between the myoma and myo-
metrium, making the enucleation of myomatous nodules and 
removal difficult. These myxoid changes may result in very 
small uterine fibroids that become too soft and difficult to vi-
sualize; thus, during myomectomy, these uterine fibroids may 
be missed. 
GnRH antagonists
GnRH antagonists act immediately to suppress the secretion 
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of FSH and LH by blocking pituitary GnRH receptors. The 
subsequent reduction in estradiol levels leads to improvement 
in bleeding patterns and a reduction in uterine fibroid size as 
early as 3 weeks after initiation of treatment [40,41]. Because 
of its rapid onset of action, and avoidance of a gonadotropin 
flare effect, patients experience faster symptom relief [42]. 
A randomized trial studied the effect of cetrorelix acetate, 
a GnRH antagonist for 4 weeks prior to surgical treatment in 
109 women, demonstrating a significant reduction in tumor 
volume and uterine volume compared with placebo [43,44]. 
A smaller, open-label study including only 19 patients re-
ported on the efficacy of ganirelix, another GnRH antagonist, 
in decreasing tumor volumes and uterine volumes over a me-
dian treatment duration of 19 days [45]. Further research into 
dosing and adverse effects is needed.
SPRMs
In vitro studies demonstrate that progesterone stimulates 
proliferative activity in cultured uterine fibroid cells, but not 
in normal myometrial cells [46]. Compared with the normal 
female myometrium, uterine fibroids overexpress ERs and pro-
gesterone receptors (PRs), and there is complex cross-talk be-
tween the ER and PR signaling pathways. It has been shown 
that uterine fibroids grow primarily during the secretory phase 
of the menstrual cycle [47,48], and exogenous progesterone 
increases mitotic activity and cellularity in this tumor [47,49]. 
An in vivo model in which human fibroid tissue was grafted 
under the kidney capsule in mice revealed that progester-
one and its receptor were essential and sufficient for tumor 
growth, as indicated by the stimulation of cell proliferation, 
the accumulation of extracellular matrix, and cellular hyper-
trophy. A number of clinical observations also support these 
findings [50]. The use of progestins in hormone-replacement 
regimens stimulates the growth of fibroids in postmenopausal 
women in a dose-dependent manner, and the addition of 
progestins to GnRH agonists diminishes the inhibitory effects 
of these agonists on uterine fibroid size [51]. Progesterone is 
therefore essential for fibroid growth, and these observations 
have stimulated research for the development of progester-
one antagonist and/or SPRM drugs [9,10,52].
SPRMs have tissue-specific effects at PRs, and they can have 
either a complete PR agonist or antagonist profile or a mixed 
agonist/antagonist profile [53]. These agents, including mife-
pristone, telapristone, onapristone, asoprisnil, and ulipristal, 
have emerged as a promising therapy for the management of 
uterine fibroids, and randomized trials have been conducted. 
Historically, mifepristone was the first PR antagonist, and it 
has been in clinical use for over 25 years now [54-56]. Much 
of the early clinical research with selective progesterone mod-
ulators involved the use of mifepristone and asoprisnil [56-
58]. Both drugs have been shown to be effective in reducing 
uterine fibroid size and improving myoma-related symptoms. 
More recently, ulipristal acetate (UPA), approved for emer-
gency contraception in the US, has been the focus of clinical 
investigations. UPA has been shown to improve quality of life, 
reduce fibroid volume, and induce amenorrhea in most of 
the women treated, and it is now approved for clinical use in 
both Europe and Canada.
Mifepristone is a synthetic 19-norsteroid SPRM with primar-
ily PR antagonist activity, and it was one of the first SPRMs to 
be developed and commonly utilized. Although mifepristone 
is most commonly recognized as RU-486, an antiprogesterone 
used as an abortifacient, it also exhibits inhibitory effects on 
uterine fibroid growth [59]. A randomized controlled trial in 
2009 assessed patients treated with mifepristone compared 
with placebo and noted a significant reduction in uterine size, 
resolution of anemia, and improvement in symptoms of men-
orrhagia [54]. A subsequent Cochrane review of 3 random-
ized controlled trials evaluating mifepristone for the treatment 
of symptomatic fibroids demonstrated significantly reduced 
bleeding and improved quality of life in users of mifepristone, 
but no significant reduction in fibroid volume [60]. Therefore, 
mifepristone was not recommended on the basis of this sys-
tematic review until better-powered randomized controlled 
trials were conducted [61].
UPA, CDB-2914 is a synthetic steroid derived from 19-nor-
progesterone [62,63], which is a selective PR modulator that 
binds to PR-A and PR-B with high affinity [64]. The binding 
and antagonist potency of UPA with the glucocorticoid recep-
tor is significantly reduced compared to mifepristone. UPA is 
tissue selective, with preferential binding noted in the uterus, 
cervix, ovaries, and hypothalamus [46,53,65]. 
Many clinical studies have evaluated the efficacy of UPA 
in the treatment of symptomatic uterine fibroids; however, 
the most widely cited studies investigating UPA include the 
European phase III studies, PGL4001 Efficacy Assessment in 
Reduction of Symptoms Due to Uterine Leiomyomata (PEARL), 
which demonstrate UPA’s safety and efficacy. 
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PEARL I compared UPA at a dosage of 5 and 10 mg/day 
with placebo for a 13-week treatment period. It effectively 
controlled uterine bleeding and reduced the size of fibroids, 
as measured by MRI compared with placebo. Rates of amen-
orrhea were high in women treated with UPA, occurring very 
early, achieved within the first 10 days after initiation of treat-
ment [66].
PEARL II was a double-blinded, noninferiority trial that in-
cluded 307 patients randomly assigned to 5 or 10 mg of UPA 
vs. a GnRH agonist, depot leuprolide acetate, for 3 months 
of treatment [67]. UPA controlled bleeding in nearly 100% of 
women, and they achieved amenorrhea 2 weeks earlier than 
women treated with leuprolide. The major benefit of UPA 
over leuprolide acetate is the reduced -hypoestrogenic side 
effects and bone loss. These differences between UPA and 
leuprolide may make UPA a preferred choice for preopera-
tive adjuvant therapy (10% vs. 40% in the leuprolide acetate 
group, P<0.001).
PEARL III assessed the efficacy and safety of long-term UPA 
treatment in women with symptomatic fibroids. Patients were 
treated with UPA 10 mg daily, followed by norethindrone 
acetate (NETA) 10 mg daily vs. placebo for 10 days. There-
after, patients could either leave the study or continue UPA 
10 mg (and NETA/placebo) for up to three 12-week courses. 
In between each 12-week course, patients received no treat-
ment and were required to have a full menses before receiving 
additional UPA treatment. The study showed that amenorrhea 
was obtained after a mean of 3.5 days in the first UPA treat-
ment period, and 2–3 days in subsequent courses. About 90% 
of women were amenorrheic after the first course, and 93%–
94% of them had spotting or no bleeding at all in the subse-
quent courses. Fibroid volume reduction reached 45% after the 
first course and continued to decrease in subsequent treatment 
rounds to 72% after the fourth treatment course [68,69].
PEARL IV was a Phase III multicenter, randomized, double-
blind, parallel group, long-term study investigating the effi-
cacy and safety of 5 and 10 mg doses of UPA during 2 treat-
ment courses. Repeated 12-week courses of daily oral UPA 
(5 and 10 mg) effectively controlled bleeding (>80%, in both 
groups) and pain, reduced fibroid volume (54% and 58%), 
and restored quality of life in patients with symptomatic fi-
broids. UPA was well tolerated with less than 5% of patients 
discontinuing treatment due to adverse events [70,71].
There has been some concern regarding endometrial 
changes induced by medium- to long-term (3–6 months) con-
tinuous daily dosing of SPRMs. Non-physiologic endometrial 
changes characterized by dilated weakly secretory endometri-
al glands with few mitotic figures, and stromal effects ranging 
from compaction to nonuniform edema have been described, 
which have been termed “progesterone receptor modulator-
associated endometrial changes (PAECs).” PAECs occur in 
approximately 50% of all patients. Additional data from the 
PEARL I, II, and III studies confirmed that PAECs were not a 
matter of concern. Endometrial thickening >16 mm occurred 
in 10%–12% of women, and endometrial histologic samples 
revealed no atypia, either simple or complex, in the treated 
groups. PAECs are reversible 1–2 months after cessation of 
UPA treatment [72,73].
Based on these advantages, UPA administration could ren-
der new established conservative treatment options for uter-
ine fibroid feasible.
Selective estrogen receptor modulators
A large body of experimental data and circumstantial evidence 
suggests that estrogen stimulates the growth of uterine fibroids 
through ER-α. The primary roles of estrogen and ER-α in myoma 
growth are permissive, in that they enable tissue to respond to 
progesterone by inducing the expression of PR [74,75].
Selective estrogen receptor modulators (SERMs) are nonste-
roidal ER ligands that display tissue-specific ER agonist and/or 
antagonist estrogenic actions via tissue-specific alterations in 
gene expression. These medications were originally used for 
the treatment of ER-positive breast cancer. Two of the most 
commonly studied SERMs in the treatment of uterine fibroids 
include tamoxifen and raloxifene [76-78]. 
Tamoxifen has an agonist action on endometrial ERs and 
carries the risk of leading to endometrial pathology. One small 
randomized, blinded controlled trial compared tamoxifen 20 
mg daily vs. placebo in women with symptomatic uterine 
fibroids. Patients were treated for a 6-month duration, and 
those receiving tamoxifen showed a significant improvement 
in menstrual blood loss but no improvement in fibroid size 
or uterine volume. The study subjects reported many side ef-
fects, including hot flush, dizziness, and benign endometrial 
thickening. Therefore, the negative side effects outweigh the 
marginal benefits of tamoxifen therapy, and its use is not rec-
ommended for the treatment of symptomatic uterine fibroids.
Raloxifene, on the other hand, displays no agonist effect 
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on the endometrium and only subtle antiestrogenic effects 
on mammary tissue [79]. A Cochrane review that included 3 
studies and a total of 215 participants evaluated the use of 
raloxifene in the treatment of symptomatic uterine fibroids. 
Two of these trials, showed the therapeutic efficacy of raloxi-
fene, but the third did not [76-78]. This review concluded that 
the effect of raloxifene on fibroid size and bleeding patterns 
is unclear; thus, larger controlled trials are needed before this 
agent can be recommended.
AIs
The mechanism underlying the gonadotropin-independent 
expression of aromatase in uterine fibroid tissue is not com-
pletely understood. It is likely that local aromatase activity in 
uterine fibroid is clinically relevant, because uterine fibroid tis-
sues from Black women — who have an increased prevalence 
of uterine fibroid and an earlier age at diagnosis, as compared 
with White women — contain high levels of aromatase, 
which result in elevated levels of estrogen in tissues [80].
AIs, exerting their effects by blocking the extragonadal 
conversion of androgens into estrogens, have become stan-
dard adjuvant therapy for postmenopausal women with ER-
positive breast cancer, as a result of their ability to produce in 
situ estrogen inhibition as compared with the indirect inhibi-
tion induced by GnRH agonists [80-82]. These properties also 
make AI very attractive candidates for the medical treatment 
of uterine fibroids. AIs are as effective as GnRH analogues in 
shrinking fibroid volume, despite stable levels of circulating 
estrogen. These observations suggest that the inhibition of 
aromatase in fibroid tissue is a key mechanism in hormone-
dependent fibroid growth. 
Two third-generation agents, letrozole (2.5 mg daily) and 
anastrozole (1 mg daily), have been studied for the treatment 
of symptomatic uterine fibroids [81,83-85]. Several small ob-
servational studies have shown a reduction in fibroid size and 
improvement of symptoms with AI therapy. Only one ran-
domized trial has compared letrozole and the GnRH agonist 
triptorelin for 12 weeks of treatment in premenopausal wom-
en with symptomatic uterine fibroids [84,85]. This Cochrane 
review of one eligible study concluded that the evidence was 
still insufficient to fully support the use of AIs for women with 
symptomatic uterine fibroids.
Conclusion
Uterine fibroids are highly prevalent in reproductive-aged 
women, and as women continue to delay childbearing, an 
increasing number of patients will require fertility-preserving 
treatment options. Medical management of uterine fibroids 
may provide symptomatic relief of the uterine fibroid-related 
symptoms along with the opportunity to maintain fertility. A 
wide range is now available and some require further evalu-
ation. Currently, GnRH agonists and SPRMs are the most ef-
fective medical therapies, with the most evidence to support 
their reduction of fibroid volume and symptomatic improve-
ment in menstrual bleeding. The choice of treatment depends 
on the patient’s personal treatment goals, as well as efficacy 
and need for repeated interventions.
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